Viking Therapeutics, Obezite İlaç Verileri Üzerine Fırlatıyor. Eli Lilly, Novo Fall.

Viking Therapeutics and Roche both reported positive trial data on their obesity treatments. Shares of Viking Therapeutics surged in premarket trading while the U.S. shares of Swiss drug giant Roche were not yet active. Weight-loss drug leaders Eli Lilly and Novo fell slightly. Viking Therapeutics (VKTX) reported that its GLP1/GIP agonist VK2735 delivered placebo-adjusted weight loss after 33 weeks. Up…